Japan pain management drugs market is anticipated to grow at a CAGR of 2.98% from 2025 to 2030.
The market growth is majorly attributed to the rising geriatric population in Japan, and low fertility rates, coupled with improving life expectancy on account of improving nutrition, low prevalence of diseases, and availability of state-of-the-art medical and pharmacological technologies in the country, which is increasing the number of older people.
According to the “Statistical Handbook of Japan 2024”, issued by the Ministry of Internal Affairs and Communication, by 2050, the population aged 65 years and above will account for 38.7% of the total population. Likewise, as per the “Annual Report on Annual Society FY2024”, as of October 2023, the population aged 74 years and above was 20.08 million and accounted for 16.1% of the total population.
Besides the growing old-age population, the chronic disease prevalence in Japan has also shown constant growth over the years, which is also anticipated to drive the demand for pain management drugs as they assist in refracting pain. According to the Global Cancer Observatory, in 2022, nearly 1,005,157 new cancer cases were reported in Japan, and the number of deaths reached 426,278. Hence, the same source also stated that prostate, lung, and stomach-related cancer cases were most commonly reported.
Moreover, the favorable policies and schemes by the Japanese government to increase healthcare access to rural societies, followed by progression in over-the-counter drug sales, have provided new growth prospects for the pain management drugs market in Japan. Likewise, various key market players, namely Shionogi Inc. and Daiichi Sankyo, have well-established customer bases in Japan, and the companies are forming strategic collaborations with global firms such as Pfizer Inc. to improve their product offering, which is estimated to stimulate the market growth.
| Report Metric | Details |
|---|---|
| Forecast Unit | Billion |
| Growth Rate | 2.98% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Drug Type, Distribution Channel, Indication, City |
| Geographical Segmentation | Tokyo, Yokohama, Osaka, Nagoya, Others |
| Companies |
|